Human Growth Hormone

Product

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

Partner

±·³Ò·¡±·³¢´¡â„¢

Growth Hormone Deficiency (Pediatric)

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase complete
Market Phase in progress

COMMERCIAL

±·³Ò·¡±·³¢´¡â„¢

Growth Hormone Deficiency (Adults)

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Market Phase not started

GLOBAL REGISTRATIONAL STRATEGIES UNDERWAY

±·³Ò·¡±·³¢´¡â„¢

Other Pediatric Indications

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Market Phase not started

PHASE 3

Immuno-Oncology

Product

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

Partner

Therapeutics LASER*

Treatment of Solid Tumors

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

IND ENABLING | PHASE 1 EXPECTED IN H1 2024

Therapeutics LASER*

Treatment of Leukemia/Lymphoma

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

IND ENABLING

Therapeutics Stealth LASER*

Treatment of Solid Tumors

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

IND ENABLING

Multispecific Immune Modulation

Hematologic Malignancies and Solid Tumors; CAR T Cells

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

Discovery-stage

*Lymphocyte Activator and Survival Extension Receptor (LASER) Antibodies

Antiviral

Product

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

Partner

HIV Trispecific Antibody

Treatment and Prevention of HIV

Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

PHASE 1

EBV Nanoparticle Vaccine

Prevention of EBV-related diseases

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

IND ENABLING

COVID Multispecific Antibody

Treatment and Prevention of COVID-19

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started

IND ENABLING